

Ulcerative Colitis

**A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors**

**Trial Status**  
Completed

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT02165215 2013-004280-31  
GA29102

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely active UC who are naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02165215 2013-004280-31 GA29102**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years & ≤ 80 Years

**Healthy Volunteers**  
No

---